Table 4.
Atopy and Measures of Asthma Control and Severity
| Non atopic n=105 | Atopic (1–3 +SPT) n=194 |
Atopic (4–7+ SPT) n=246 |
Atopic (8+ SPT) n=134 |
p value | p value (trend) | |
|---|---|---|---|---|---|---|
|
| ||||||
| Asthma Symptoms | Mean days (SD)/past 2 weeks | |||||
|
| ||||||
| Cough, wheeze or shortness of breath | 3.5 (4.1) | 3.1 (3.9) | 2.7 (3.5) | 3.4 (4.1) | 0.09 | 0.58 |
|
| ||||||
| Nocturnal | 2.4 (3.8) | 2.3 (4.0) | 1.8 (3.4) | 1.8 (3.0) | 0.20 | 0.07 |
|
| ||||||
| Days of SABA use | 4.1 (4.7) | 4.4 (5.0) | 4.2 (5.0) | 4.5 (4.9) | 0.74 | 0.89 |
|
| ||||||
| Uncontrolled asthma, %* | 57.0 | 50.3 | 55.5 | 54.6 | 0.64 | 0.87 |
|
| ||||||
| Acute care utilization | Yes (%) over past 12 months | |||||
|
| ||||||
| Hospitalization, | 18 (17.1) | 40 (20.6) | 71 (29.0) | 28 (20.9) | 0.05 | 0.17 |
|
| ||||||
| ED | 88 (83.8) | 160 (82.5) | 184 (74.8) | 105 (78.4) | 0.14 | 0.09 |
|
| ||||||
| Lung function | Mean (SD) | |||||
|
| ||||||
| FEV1 % predicted | 97.9 (18.4) | 97.9 (16.5) | 95.4 (17.4) | 92.7 (20.3) | 0.14 | 0.04 |
|
| ||||||
| FVC % predicted | 99.2 (16.2) | 101.0 (15.1) | 100.0 (16.2) | 97.9 (15.9) | 0.24 | 0.43 |
|
| ||||||
| FEV1/FVC | 84.0 (7.9) | 82.4 (7.9) | 81.6 (8.4) | 79.1 (8.7) | <0.001 | <0.001 |
|
| ||||||
| FeNO, median (IQR) | 8 (5,13) | 13 (8,32) | 21 (11,38) | 25 (13,46) | <0.001 | <0.001 |
|
| ||||||
| Medications and Severity, Mean (SD)
| ||||||
| Treatment Step, n (%) | 0.005 | 0.001 | ||||
| 1 | 29 (29.0) | 40 (22.5) | 29 (12.7) | 20 (16.3) | ||
| 2 | 22 (22.0) | 47 (26.4) | 43 (18.9) | 20 (16.3) | ||
| 3 | 12 (12.0) | 28 (15.7) | 43 (18.9) | 24 (19.5) | ||
| 4 | 1 (1.0) | 5 (2.8) | 14 ( 6.1) | 7 (5.7) | ||
| 5 | 36 (36.0) | 58 ( 32.6) | 99 (43.4) | 52 (42.3) | ||
|
| ||||||
| Asthma Severity Score | 6.0 (3.5) | 6.0 (3.4) | 6.6 (3.3) | 7.2 (3.5) | 0.02 | 0.003 |
*
SABA - Short-acting beta agonist use
**
uncontrolled=ACT (Asthma Control Test) score ≤ 19
1st p value test for difference between groups using Kruskal-Wallis or Chi Square.
2nd p value for trend